Skip to main content

Articles

Page 22 of 22

  2. Dimebon (latrepirdine) has received widespread publicity as a potential therapy for Alzheimer's disease following a very positive phase 2 study carried out in Russia and published in the Lancet in 2008. In this s...

    Authors: Roy W Jones

    Citation: Alzheimer's Research & Therapy 2010 2:25

    Content type: Commentary

    Published on:

  3. Atrophy measured on structural magnetic resonance imaging (sMRI) is a powerful biomarker of the stage and intensity of the neurodegenerative aspect of Alzheimer's disease (AD) pathology. In this review, we wil...

    Authors: Prashanthi Vemuri and Clifford R Jack Jr

    Citation: Alzheimer's Research & Therapy 2010 2:23

    Content type: Review

    Published on:

  4. The present review of Alzheimer's disease (AD) rating scales aims to outline the need for a new rating scale to be used in routine clinical practice for long-term medical care of AD patients. An ideal scale would...

    Authors: Philippe Robert, Steven Ferris, Serge Gauthier, Ralf Ihl, Bengt Winblad and Frank Tennigkeit

    Citation: Alzheimer's Research & Therapy 2010 2:24

    Content type: Research

    Published on:

  6. Since the reformulation of the amyloid cascade hypothesis to focus on oligomeric aggregates of amyloid beta as the prime toxic species causing Alzheimer's disease, many researchers refocused on detecting a spe...

    Authors: Kerensa Broersen, Frederic Rousseau and Joost Schymkowitz

    Citation: Alzheimer's Research & Therapy 2010 2:12

    Content type: Review

    Published on:

  8. Recently, it has become clear that head trauma can lead to a progressive neurodegeneration known as chronic traumatic encephalopathy. Although the medical literature also implicates head trauma as a risk facto...

    Authors: Brandon E Gavett, Robert A Stern, Robert C Cantu, Christopher J Nowinski and Ann C McKee

    Citation: Alzheimer's Research & Therapy 2010 2:18

    Content type: Commentary

    Published on:

  9. Recent advances in biomarkers for Alzheimer's disease (AD) now allow the visualization of one of the hallmark pathologies of AD in vivo, and combination biomarker profiles can now approximate the diagnostic accur...

    Authors: Reisa Sperling and Keith Johnson

    Citation: Alzheimer's Research & Therapy 2010 2:17

    Content type: Viewpoint

    Published on:

  11. Matrix metalloproteinases (MMP) are believed to be involved in the pathologic processes behind Alzheimer's disease (AD). In this study, we aimed to examine the cerebrospinal fluid (CSF) levels of MMPs and tiss...

    Authors: Erik Stomrud, Maria Björkqvist, Sabina Janciauskiene, Lennart Minthon and Oskar Hansson

    Citation: Alzheimer's Research & Therapy 2010 2:20

    Content type: Research

    Published on:

  12. Evidence from clinical samples and geographically limited population studies suggests that vascular health, diabetes and apolipoprotein ε4 (APOE) are associated with dementia.

    Authors: David J Llewellyn, Iain A Lang, Fiona E Matthews, Brenda L Plassman, Mary AM Rogers, Lewis B Morgenstern, Gwenith G Fisher, Mohammed U Kabeto and Kenneth M Langa

    Citation: Alzheimer's Research & Therapy 2010 2:19

    Content type: Research

    Published on:

  21. The amyloid hypothesis provides a basis for the development of new therapeutic strategies in Alzheimer's disease. Two large trials have recently been published. The first is a phase 2 study of passive immunoth...

    Authors: Niels D Prins, Pieter Jelle Visser and Philip Scheltens

    Citation: Alzheimer's Research & Therapy 2010 2:5

    Content type: Commentary

    Published on:

  23. LY450139 (semagacestat) inhibits γ-secretase, a key enzyme for generation of amyloid β (Aβ), the peptide deposited in plaques in Alzheimer disease (AD). Previous data have shown that LY450139 lowers plasma Aβ,...

    Authors: Erik Portelius, Robert A Dean, Mikael K Gustavsson, Ulf Andreasson, Henrik Zetterberg, Eric Siemers and Kaj Blennow

    Citation: Alzheimer's Research & Therapy 2010 2:7

    Content type: Research

    Published on:

  24. Since the 1990s, the genetics of Alzheimer disease (AD) has been an active area of research. The identification of deterministic mutations in the APP, PSEN1, and PSEN2 genes responsible for early-onset autosomal ...

    Authors: Nilüfer Ertekin-Taner

    Citation: Alzheimer's Research & Therapy 2010 2:3

    Content type: Review

    Published on:

  25. Clinicians need to predict prognosis of Alzheimer's disease (AD), and researchers need models of progression to develop biomarkers and clinical trials designs. We tested a calculated initial progression rate t...

    Authors: Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby and Wenyaw Chan

    Citation: Alzheimer's Research & Therapy 2010 2:2

    Content type: Research

    Published on:

    The Erratum to this article has been published in Alzheimer's Research & Therapy 2010 2:14

  27. There are no empiric data to support guidelines for duration of therapy with antidementia drugs. This study examined whether persistent use of antidementia drugs slows clinical progression of Alzheimer disease...

    Authors: Susan D Rountree, Wenyaw Chan, Valory N Pavlik, Eveleen J Darby, Samina Siddiqui and Rachelle S Doody

    Citation: Alzheimers Res Ther 2009 1:7

    Content type: Research

    Published on:

  28. Amyloid is deposited in the walls of arteries and capillaries as cerebral amyloid angiopathy (CAA) in the brains of older individuals and of those with Alzheimer disease (AD). CAA in AD reflects an age-related...

    Authors: Roy O Weller, Stephen D Preston, Malavika Subash and Roxana O Carare

    Citation: Alzheimer's Research & Therapy 2009 1:6

    Content type: Review

    Published on:

  30. Identifying the causes of dementia is important in the search for effective preventative and treatment strategies. The concept of mild cognitive impairment (MCI), as prodromal dementia, has been useful but rem...

    Authors: Blossom CM Stephan, Fiona E Matthews, Kay-Tee Khaw, Carole Dufouil and Carol Brayne

    Citation: Alzheimers Res Ther 2009 1:4

    Content type: Review

    Published on:

Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Alzheimer's Research & Therapy

ISSN: 1758-9193